Brokerages Set Esperion Therapeutics, Inc. (ESPR) PT at $60.73

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) have been assigned a consensus rating of “Buy” from the fifteen research firms that are currently covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $60.73.

A number of brokerages have recently issued reports on ESPR. Northland Securities reiterated a “buy” rating and set a $72.00 target price on shares of Esperion Therapeutics in a research report on Friday, November 10th. Stifel Nicolaus reiterated a “buy” rating and set a $70.00 target price on shares of Esperion Therapeutics in a research report on Wednesday, October 4th. Cowen and Company began coverage on Esperion Therapeutics in a research report on Thursday, September 7th. They set an “outperform” rating and a $64.00 target price on the stock. Zacks Investment Research upgraded Esperion Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 23rd. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $85.00 target price on shares of Esperion Therapeutics in a research report on Monday, August 21st.

Shares of Esperion Therapeutics (NASDAQ:ESPR) traded up $1.77 during trading hours on Monday, hitting $49.49. The stock had a trading volume of 495,757 shares, compared to its average volume of 1,051,113. Esperion Therapeutics has a 52-week low of $10.30 and a 52-week high of $57.40.

Esperion Therapeutics (NASDAQ:ESPR) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.79) by ($0.07). During the same quarter in the previous year, the firm posted ($0.77) earnings per share. analysts expect that Esperion Therapeutics will post -7.21 earnings per share for the current fiscal year.

A number of hedge funds have recently made changes to their positions in the business. Iguana Healthcare Management LLC lifted its holdings in Esperion Therapeutics by 50.0% in the 3rd quarter. Iguana Healthcare Management LLC now owns 150,000 shares of the biopharmaceutical company’s stock valued at $7,518,000 after purchasing an additional 50,000 shares in the last quarter. California Public Employees Retirement System raised its holdings in shares of Esperion Therapeutics by 14.9% during the 3rd quarter. California Public Employees Retirement System now owns 48,158 shares of the biopharmaceutical company’s stock worth $2,414,000 after acquiring an additional 6,258 shares during the period. Perceptive Advisors LLC purchased a new position in shares of Esperion Therapeutics during the 3rd quarter worth $540,000. Caisse DE Depot ET Placement DU Quebec purchased a new position in shares of Esperion Therapeutics during the 3rd quarter worth $12,583,000. Finally, OxFORD Asset Management LLP purchased a new position in shares of Esperion Therapeutics during the 3rd quarter worth $715,000. Institutional investors own 89.12% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another website, it was illegally copied and republished in violation of United States & international trademark & copyright law. The original version of this story can be viewed at https://www.com-unik.info/2017/11/16/brokerages-set-esperion-therapeutics-inc-espr-pt-at-60-73.html.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

What are top analysts saying about Esperion Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Esperion Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit